-
FDA extends review time of AstraZeneca's vandetanib
LONDON — A new drug application for Anglo-Swedish drug maker AstraZeneca's vandetanib has been extended.
The drug maker recently announced that the Food and Drug Administration asked AstraZeneca to submit a Risk Evaluation and Mitigation Strategy, which accordingly extended the Prescription Drug User Fee Act from Jan. 7 to April 7.
AstraZeneca will continue to work closely with the FDA to support the review of vandetanib, a drug for treating patients with advanced medullary thyroid cancer.
-
Roche's CFO to retire
BASEL, Switzerland — Roche CFO Erich Hunziker will retire from the company at the end of March, the Swiss drug maker said Monday.
Hunziker was appointed CFO and a member of the corporate executive committee in 2001, and last year took on the additional role of chief information officer.
Alan Hippe, a former executive from German tire maker Continental and manufacturer ThyssenKrupp, will replace Hunziker as CFO.